Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Palliative care needs of advanced cancer patients in the emergency department at the end of life: an observational cohort study.

Verhoef MJ, de Nijs E, Horeweg N, Fogteloo J, Heringhaus C, Jochems A, Fiocco M, van der Linden Y.

Support Care Cancer. 2019 Jun 13. doi: 10.1007/s00520-019-04906-x. [Epub ahead of print]

PMID:
31197539
2.

Health-related quality of life of breast cancer patients after accelerated partial breast irradiation using intraoperative or external beam radiotherapy technique.

Jacobs DHM, Horeweg N, Straver M, Roeloffzen EMA, Speijer G, Merkus J, van der Sijp J, Mast ME, Fisscher U, Petoukhova AL, Zwanenburg AG, Marijnen CAM, Koper PCM.

Breast. 2019 Aug;46:32-39. doi: 10.1016/j.breast.2019.04.006. Epub 2019 Apr 28.

PMID:
31075670
3.

Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer.

Horeweg N, Creutzberg CL, Rijkmans EC, Laman MS, Velema LA, Coen VLMA, Stam TC, Kerkhof EM, Kroep JR, de Kroon CD, Nout RA.

Int J Gynecol Cancer. 2019 Jan 10. pii: ijgc-2018-000057. doi: 10.1136/ijgc-2018-000057. [Epub ahead of print]

PMID:
30630883
4.

Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

Marinkovic M, Horeweg N, Laman MS, Bleeker JC, Ketelaars M, Peters FP, Luyten GPM, Creutzberg CL.

Br J Ophthalmol. 2018 Aug;102(8):1154-1159. doi: 10.1136/bjophthalmol-2017-310688. Epub 2017 Nov 9.

PMID:
29122824
5.

Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.

Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, Bleeker JC, Ketelaars M, Luyten GP, Creutzberg CL.

Eur J Cancer. 2016 Nov;68:106-113. doi: 10.1016/j.ejca.2016.09.009. Epub 2016 Oct 12.

PMID:
27741435
6.

An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management.

Slatore CG, Horeweg N, Jett JR, Midthun DE, Powell CA, Wiener RS, Wisnivesky JP, Gould MK; ATS Ad Hoc Committee on Setting a Research Framework for Pulmonary Nodule Evaluation.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):500-14. doi: 10.1164/rccm.201506-1082ST.

7.

Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study.

Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H.

J Thorac Oncol. 2015 May;10(5):747-53. doi: 10.1097/JTO.0000000000000488.

8.

Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?

Scholten ET, de Jong PA, de Hoop B, van Klaveren R, van Amelsvoort-van de Vorst S, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Vernhout RM, Groen HJ, Lammers JW, van Ginneken B, Jacobs C, Mali WP, Horeweg N, Weenink C, Thunnissen E, Prokop M, Gietema HA.

Eur Respir J. 2015 Mar;45(3):765-73. doi: 10.1183/09031936.00005914. Epub 2014 Nov 27. Erratum in: Eur Respir J. 2015 May;45(5):1517.

9.

Interscan variation of semi-automated volumetry of subsolid pulmonary nodules.

Scholten ET, de Jong PA, Jacobs C, van Ginneken B, van Riel S, Willemink MJ, Vliegenthart R, Oudkerk M, de Koning HJ, Horeweg N, Prokop M, Mali WP, Gietema HA.

Eur Radiol. 2015 Apr;25(4):1040-7. doi: 10.1007/s00330-014-3478-1. Epub 2014 Nov 21.

PMID:
25413965
10.

Detection and quantification of the solid component in pulmonary subsolid nodules by semiautomatic segmentation.

Scholten ET, Jacobs C, van Ginneken B, van Riel S, Vliegenthart R, Oudkerk M, de Koning HJ, Horeweg N, Prokop M, Gietema HA, Mali WP, de Jong PA.

Eur Radiol. 2015 Feb;25(2):488-96. doi: 10.1007/s00330-014-3427-z. Epub 2014 Oct 7.

PMID:
25287262
11.

Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.

Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, ten Haaf K, Nackaerts K, Lammers JW, Weenink C, Groen HJ, van Ooijen P, de Jong PA, de Bock GH, Mali W, de Koning HJ, Oudkerk M.

Lancet Oncol. 2014 Nov;15(12):1332-41. doi: 10.1016/S1470-2045(14)70389-4. Epub 2014 Oct 1.

PMID:
25282285
12.

Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.

Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, Nackaerts K, Vliegenthart R, ten Haaf K, Yousaf-Khan UA, Heuvelmans MA, Thunnissen E, Oudkerk M, Mali W, de Koning HJ.

Lancet Oncol. 2014 Nov;15(12):1342-50. doi: 10.1016/S1470-2045(14)70387-0. Epub 2014 Oct 1.

PMID:
25282284
13.

Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening.

Scholten ET, Horeweg N, de Koning HJ, Vliegenthart R, Oudkerk M, Mali WP, de Jong PA.

Eur Radiol. 2015 Jan;25(1):81-8. doi: 10.1007/s00330-014-3394-4. Epub 2014 Sep 4.

PMID:
25187382
14.

The importance of screening for lung cancer.

Horeweg N, de Koning H.

Expert Rev Respir Med. 2014 Oct;8(5):597-614. doi: 10.1586/17476348.2014.937428. Epub 2014 Aug 27. Review.

PMID:
25158921
15.

Low-dose computed tomography screening for lung cancer: results of the first screening round.

Horeweg N, Nackaerts K, Oudkerk M, de Koning HJ.

J Comp Eff Res. 2013 Sep;2(5):433-6. doi: 10.2217/cer.13.57.

PMID:
24236740
16.

Reply: stage distribution of lung cancers detected by computed tomography screening in the NELSON Trial.

Horeweg N, de Koning HJ.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):1035-6. doi: 10.1164/rccm.201305-0935LE. No abstract available.

PMID:
24127806
17.

Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial.

Horeweg N, van der Aalst CM, Vliegenthart R, Zhao Y, Xie X, Scholten ET, Mali W, Thunnissen E, Weenink C, Groen HJ, Lammers JW, Nackaerts K, van Rosmalen J, Oudkerk M, de Koning HJ.

Eur Respir J. 2013 Dec;42(6):1659-67. doi: 10.1183/09031936.00197712. Epub 2013 Jul 11.

18.

Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial.

Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJ, Lammers JW, Aerts JG, Scholten ET, van Rosmalen J, Mali W, Oudkerk M, de Koning HJ.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):848-54. doi: 10.1164/rccm.201209-1651OC.

PMID:
23348977
19.

Blinded and uniform cause of death verification in a lung cancer CT screening trial.

Horeweg N, van Klaveren RJ, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Mali W, Oudkerk M, de Koning HJ.

Lung Cancer. 2012 Sep;77(3):522-5. doi: 10.1016/j.lungcan.2012.04.018. Epub 2012 May 22.

20.

Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial.

Van't Westeinde SC, Horeweg N, De Leyn P, Groen HJ, Lammers JW, Weenink C, Nackaerts K, van Klaveren RJ.

Eur J Cardiothorac Surg. 2012 Sep;42(3):420-9. doi: 10.1093/ejcts/ezs081. Epub 2012 Apr 5.

PMID:
22491665
21.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJM, Lammers JJ, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

Chest. 2012 Aug;142(2):377-384. doi: 10.1378/chest.11-2030.

PMID:
22302298

Supplemental Content

Loading ...
Support Center